233 related articles for article (PubMed ID: 28350084)
1. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract][Full Text] [Related]
2. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
[TBL] [Abstract][Full Text] [Related]
3. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
4. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.
Tang J; Sui CJ; Wang DF; Lu XY; Luo GJ; Zhao Q; Lian QY; Jeong S; Lin XM; Zhu YJ; Zheng B; Wu R; Wang Q; Liu XL; Liu JF; Xia Q; Wu G; Gu J; Wang HY; Chen L
Theranostics; 2020; 10(12):5384-5397. PubMed ID: 32373219
[No Abstract] [Full Text] [Related]
5. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Huang FY; Wong DK; Tsui VW; Seto WK; Mak LY; Cheung TT; Lai KK; Yuen MF
BMC Cancer; 2019 Aug; 19(1):789. PubMed ID: 31395065
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
Li W; Wu H; Xu X; Zhang Y
Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349
[TBL] [Abstract][Full Text] [Related]
8. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.
Li X; Xu W; Kang W; Wong SH; Wang M; Zhou Y; Fang X; Zhang X; Yang H; Wong CH; To KF; Chan SL; Chan MTV; Sung JJY; Wu WKK; Yu J
Theranostics; 2018; 8(6):1740-1751. PubMed ID: 29556353
[No Abstract] [Full Text] [Related]
9. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
11. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.
Woo HG; Wang XW; Budhu A; Kim YH; Kwon SM; Tang ZY; Sun Z; Harris CC; Thorgeirsson SS
Gastroenterology; 2011 Mar; 140(3):1063-70. PubMed ID: 21094160
[TBL] [Abstract][Full Text] [Related]
12. SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Lee YS; Kim BH; Kim BC; Shin A; Kim JS; Hong SH; Hwang JA; Lee JA; Nam S; Lee SH; Bhak J; Park JW
Oncotarget; 2015 Jun; 6(18):16449-60. PubMed ID: 25965825
[TBL] [Abstract][Full Text] [Related]
13. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
Lin J; Zhao S; Wang D; Song Y; Che Y; Yang X; Mao J; Xie F; Long J; Bai Y; Yang X; Zhang L; Bian J; Lu X; Sang X; Pan J; Wang K; Zhao H
Front Immunol; 2021; 12():673248. PubMed ID: 34211467
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
Personeni N; Rimassa L; Pressiani T; Destro A; Ligorio C; Tronconi MC; Bozzarelli S; Carnaghi C; Di Tommaso L; Giordano L; Roncalli M; Santoro A
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1179-87. PubMed ID: 23568548
[TBL] [Abstract][Full Text] [Related]
15. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
16. TP53 rs28934571 polymorphism increases the prognostic risk in hepatocellular carcinoma.
Zhao Y; Zhu C; Chang Q; Yang J; Liu Y; Peng P; Liu C; Cheng R; Chen X; Wu Y; Cheng L; Hu L; Wu X; Yin J
Biomark Med; 2021 Jun; 15(9):615-622. PubMed ID: 34037458
[No Abstract] [Full Text] [Related]
17. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
18. Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
Xu J; Liang J; Meng YM; Yan J; Yu XJ; Liu CQ; Xu L; Zhuang SM; Zheng L
Clin Cancer Res; 2017 Aug; 23(15):4482-4492. PubMed ID: 28223275
[No Abstract] [Full Text] [Related]
19. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
20. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
